Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate

Stock Information for Acer Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Acer Therapeutics Inc.

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIN, TWNK, PNT, ACER
Moore Kuehn Encourages TWNK, LVOX, ACER, and PNT Investors to Contact Law Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, HT, ABCM, ACER
ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NXGN, AVTA, SPLK, ACER
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - AGE, NEWR, CCF, ACER
Moore Kuehn Encourages AGE, ACER, NXGN, and SUM Investors to Contact Law Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.